Molecular Forms of Glucagon-Like Peptide-1 in Human Pancreas and Glucagonomas
- 1 September 1985
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 61 (3) , 472-479
- https://doi.org/10.1210/jcem-61-3-472
Abstract
The structure of human preproglucagon, as deduced from nucleotide sequencing of the preproglucagon gene, contains two glucagon-like peptides (GLP-1 and GLP-2) in the portion C-terminal to glucagon. A rabbit antiserum was raised against synthetic GLP-1-(1–19) which had 20% cross-reactivity with synthetic GLP-1 and des-Gly37-GLP-l amide, two possible forms of the GLP-1 whole molecule, but no significant crossreactivity with glucagon or other pancreatic peptides. Immunocytochemistry revealed that the distribution of GLP-1-(1–19) immunoreactivity followed that of glucagon-like immunoreactivity in the normal human pancreas and in two human glucagonsecreting pancreatic tumors. Chromatography of human pancreas extracts on Sephadex G-50 gave peaks of cross-reactivity at Kav values of 0.06–0.16, 0.34–0.39, 0.54–0.58 (the elution position of synthetic GLP-1), and 0.64–0.70. The concentration of immunoreactivity in the Kav 0.54–0.58 peak measured by RIA using GLP-1 or des-Gly37-GLP-l amide as standard was 94 ± 7 pmol/g (mean ± SEM), while the total pancreatic glucagon content was 4.8 ± 0.8 nmol/g. One extract of a human glucagonsecreting pancreatic tumor contained a prominent peak of GLP-1–(1–19) peptide cross-reactivity with properties identical to those of GLP-1 or des-Gly37-GLP-l amide on gel filtration and reverse phase high pressure liquid chromatography, but another tumor contained a preponderance of cross-reactive forms of greater molecular size. Pretreatment plasma from three patients with radiological and biochemical evidence of glucagon-secreting tumors contained a peak of cross-reactivity with the chromatographic properties of intact GLP-1. The low concentrations of intact GLP-1 in normal pancreas compared with pancreatic glucagon concentrations suggest that the majority of the proglucagon is cleaved in a manner that does not produce GLP-1, as defined by its delimiting pairs of basic amino acid residues.Keywords
This publication has 10 references indexed in Scilit:
- Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreasHistochemistry and Cell Biology, 1984
- Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences.Proceedings of the National Academy of Sciences, 1984
- Molecular Forms of Human Enteroglucagon in Tissue and Plasma: Plasma Responses to Nutrient Stimuli in Health and in Disorders of the Upper Gastrointestinal Tract*Journal of Clinical Endocrinology & Metabolism, 1983
- Mammalian pancreatic preproglucagon contains three glucagon-related peptides.Proceedings of the National Academy of Sciences, 1983
- Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA.Journal of Biological Chemistry, 1983
- MOLECULAR HETEROGENEITY OF GLUCAGON IN NORMAL SUBJECTS AND IN PATIENTS WITH GLUCAGON-PRODUCING TUMORS1983
- Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.Proceedings of the National Academy of Sciences, 1982
- The primary structure of porcine glicentin (proglucagon)Regulatory Peptides, 1981
- Relationship of glicentin to proglucagon and glucagon in the porcine pancreasNature, 1981
- THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITYBiochemical Journal, 1963